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Abstract Vascular endothelial growth factor (VEGF) is a
key regulator of angiogenesis which drives endothelial
cell survival, proliferation, and migration while increas-
ing vascular permeability. Playing an important role in
the physiology of normal ovaries, VEGF has also been
implicated in the pathogenesis of ovarian cancer. Essen-
tially by promoting tumor angiogenesis and enhancing
vascular permeability, VEGF contributes to the develop-
ment of peritoneal carcinomatosis associated with malig-
nant ascites formation, the characteristic feature of
advanced ovarian cancer at diagnosis. In both experi-
mental and clinical studies, VEGF levels have been
inversely correlated with survival. Moreover, VEGF
inhibition has been shown to inhibit tumor growth and
ascites production and to suppress tumor invasion and
metastasis. These findings have laid the basis for the
clinical evaluation of agents targeting VEGF signaling
pathway in patients with ovarian cancer. In this review,
we will focus on VEGF involvement in the pathophysiology
of ovarian cancer and its contribution to the disease
progression and dissemination.
Keywords Angiogenesis . Bevacizumab .Malignant
ascites . Ovarian cancer . Peritoneal carcinomatosis .
Vascular endothelial growth factor
1 Introduction
Vascular endothelial growth factor (VEGF), a potent cytokine
and a key regulator of physiological and pathological
angiogenesis, has a major contribution to diverse pathological
processes, in particular tumorigenesis [1]. In women, an
exceptional role is played by VEGF through its involvement
in ovarian biology. Closely linked to the normal function of
ovaries, VEGF is also implicated in ovarian pathologies,
including malignant neoplasms [2]. Ovarian cancer, the
seventh leading cancer in women and the second cause of
death from gynecologic malignancies worldwide [3], is a
richly vascularized tumor that is known to be highly
dependent on VEGF-mediated angiogenesis [4]. While
representing a crucial, early event in ovarian carcinogenesis
[5], VEGF expression is associated with tumor growth and
aggression, as well as poor survival [6–8].
Peritoneal seeding is the most common pathway for the
spread of ovarian cancer [9]. At diagnosis, about two thirds of
the patients with ovarian cancer have already developed
peritoneal carcinomatosis [10] and more than one third present
with malignant ascites [11]. Both tumor burden and ascites are
inversely associated with survival [12, 13]. Basically through
promoting tumor angiogenesis and enhancing the vascular
permeability, VEGF has been implicated in the peritoneal
dissemination of ovarian cancer and the subsequent develop-
ment of malignant ascites, further highlighting the key
importance of VEGF in the pathophysiology of the disease.
Here, we review different aspects of VEGF contribution to
ovarian cancer, address VEGF-targeted strategies as a
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therapeutic approach to the disease, and present the latest
clinical data on the subject.
2 Vascular endothelial growth factor
2.1 Identification
In 1983, the identification of a polypeptide from the
conditioned medium of a guinea pig tumor cell line was
reported by Senger et al. [14]. To reflect its role in
enhancing the permeability of tumor vasculature, they
designated this polypeptide “vascular permeability factor
(VPF).” Later in 1989, Ferrara and Henzel [15] isolated a
potent endothelial mitogen from the conditioned media of
bovine pituitary follicular cells and named it vascular
endothelial growth factor to show its specificity for
endothelial cells. In the same year and based on the work
by Senger et al., the isolation and sequencing of human
VPF from U937 cells were independently reported by
Connolly et al. [16]. Following cDNA cloning of VEGF
and VPF, it was eventually revealed that these molecules
were the same [17, 18].
2.2 VEGF and its receptors
VEGF family include VEGF-A (hereafter VEGF), VEGF-
B, VEGF-C, VEGF-D, placenta growth factor (PlGF),
VEGF-E (viral VEGF homologs), and VEGF-F (snake
venom VEGFs) [19]. VEGF is a 45-kDa heparin-binding
homodimeric glycoprotein [15]. At least 14 various iso-
forms of VEGF result from alternative splicing [20].
VEGF165 is the most abundant and mitogenic isoform
which exists as both extracellular matrix-bound and freely
diffusible protein. Plasmin and various metalloproteinases
can split the bound fraction into bioactive fragments
VEGF110 or VEGF113 [21]. VEGF121 is a freely diffusible
protein that does not bind to heparin. VEGF189 and
VEGF206 are longer, heparin-binding isoforms which might
also undergo extracellular proteolysis to generate bioactive,
diffusible fragments [22]. Thus, VEGF proteins may
become available to endothelial cells by at least two
different mechanisms: alternative splicing and proteolytic
cleavage. Besides, differential ability of VEGF isoforms in
binding to the extracellular matrix generates an “angiogenic
gradient” that is now considered of importance in a variety
of pathophysiological conditions [23].
VEGF binding sites include three receptor tyrosine
kinases (RTK) called vascular endothelial growth factor
receptor (VEGFR)-1, VEGFR-2, and VEGFR-3 (Fig. 1).
VEGF family members show differential affinity for their
receptors. VEGF, VEGF-B, and PlGF can bind and activate
VEGFR-1, whereas VEGFR-2 is primarily activated by
VEGF, and VEGFR-3 activation is only triggered by
VEGF-C and VEGF-D [24].
Neuropilins (NRPs) have also been implicated in
VEGFR activation [25]. In endothelial cells, NRP-1 is
thought to act primarily as a co-receptor for VEGF-A165 by
forming complexes with VEGFR-2. VEGFRs were identi-
fied initially on the cell surface of vascular endothelial cells
[26, 27] and, subsequently, on bone marrow-derived cells
such as monocytes [28]. VEGFR-1 expression has been
observed in vascular endothelial cells and a range of non-
endothelial cells including hematopoietic stem cells,
monocytes, and macrophages [29]. VEGFR-2 is expressed
in vascular endothelial cells and, at lower levels, in
neurons, osteoblasts, pancreatic duct cells, retinal progen-
itor cells, and megakaryocytes [30]. VEGFR-3 expression
seems to be largely restricted to lymphatic endothelial
cells [31]. VEGFRs, like other RTKs, become activated
when ligand–receptor binding and resultant dimerization
happen. Subsequent autophosphorylation on certain tyro-
sine residues triggers intracellular signaling cascade
mediated by several effectors. Although VEGFR-1 affinity
for VEGF is tenfold higher than that of VEGFR-2, VEGF
activation of VEGFR-2 is much more significant. Thus,
VEGFR-2 represents the major mediator of VEGF-driven
responses in endothelial cells promoting angiogenesis and
vascular permeability [21].
2.3 Biological effects of VEGF
VEGF biologically affects angiogenesis, hematopoiesis,
hemodynamics, and vascular homeostasis. VEGF drives
endothelial cell survival, proliferation, migration, and tube
formation. Anti-apoptotic activity of VEGF is in part
mediated through the activation of PI3K/Akt pathway
[32]. VEGF also prevents endothelial apoptosis by inducing
the expression of apoptosis-regulating proteins such as Bcl-
2, A1 [33], XIAP, and survivin [34]. Acting as an
endothelial cell mitogen [35], VEGF promotes sprouting
of vascular endothelial cells during physiological and tumor
angiogenesis. In addition, VEGF controls hematopoietic
stem cells’ survival during hematopoietic repopulation and
plays an important role in regulating the differentiation of
endothelial progenitor cells and their migration to regions
of neoangiogenesis in adults [1]. Moreover, VEGF enhan-
ces vascular permeability to water and large molecular
weight proteins [36], a process in which p38 MAPK
pathway has been implicated as an essential mediator
[37]. VEGF also stimulates nitric oxide-mediated vasodila-
tation [38]. VEGF, at low physiological levels, maintains
vascular homeostasis in vascularized tissues, especially in
fenestrated and sinusoidal vessels in endocrine and secre-
tory organs as well as large blood vessels, skeletal muscle,
and myocardium [39].
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2.3.1 VEGF and physiological processes
VEGF promotes physiological angiogenesis activated in
embryonic and postnatal development, skeletal growth, and
endochondral bone formation [40]. Apart from its unique
contribution to ovarian physiology described below, VEGF
mediates other angiogenic processes in adults, such as
wound healing [41, 42], tissue regeneration after injury and
ischemia [43, 44], and exercise-induced angiogenesis in
skeletal muscle [45].
The ovary is distinct from other endocrine organs in that
it undergoes repetitive cycles of angiogenesis within its
various glandular compartments [46]. VEGF expression
and production within the ovary are critical for normal
reproductive function [2]. Increased intrafollicular VEGF
has been shown during the initial part of the ovulatory
cycle, with peak concentrations just before the start of the
luteal phase [47]. By driving thecal vascularization, VEGF
supports the cyclic growth, development, and maturation of
the follicle; ovulation; and associated endocrine changes.
Consistently, VEGF inhibition in different stages of
follicular phase can disrupt these normal events [46, 48–
52]. As a permeability factor, VEGF is proposed to
modulate differential vascular permeability leading to the
preferential accumulation of gonadotropins within the
dominant follicle, hence its likely involvement in the
process of follicular selection [2]. In addition, VEGF might
mediate the preovulatory increase in follicular vascular
permeability and the resulting edema, a mechanism
contributing to ovulation [53]. VEGF is also essential for
corpus luteum angiogenesis [54] as inhibition of VEGF has
a profound inhibitory effect upon luteal function [55].
Coexpression of VEGF and its receptors by granulosa cells
has attributed another potentially important function to
VEGF [56]. It has been suggested that VEGF may directly
modulate the function of these cells by promoting cell
survival [57], proliferation [56, 58], and/or migration [59].
2.3.2 VEGF in nonmalignant disorders
VEGF has been implicated in various pathological con-
ditions. Besides performing stabilizing functions in the
developing retinal vasculature [60], VEGF has strikingly
been correlated with intraocular neovascular syndromes
Fig. 1 Vascular endothelial growth factor (VEGF) family and their
receptors. VEGF family members bind to specific receptor tyrosine
kinases VEGFR-1, VEGFR-2, and VEGFR-3 and, through activating
different cascades, exert their various biologic effects. VEGFR-2
represents the major mediator of VEGF-driven responses in endothe-
lial cells responsible for most VEGF angiogenic activities. Neuropilins
(NRP-1 and NRP-2) are known as co-receptors for VEGF
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such as retinopathy of prematurity [61], diabetic retinopa-
thy [62], central retinal vein occlusion [63], and neo-
vascular age-related macular degeneration [64]. It has also
been shown that VEGF may be an important mediator of
such inflammatory disorders as psoriasis [65], rheumatoid
arthritis [66], osteoarthritis [67], human renal [68] and
cardiac [69] allograft rejection, as well as blood–brain
barrier breakdown and the resulting edema in acute brain
injury[70]. In addition, VEGF contribution to some
cardiovascular diseases has been reported, including infan-
tile hemangiomas [71], atherosclerosis [72], ischemic heart
disease [73], peripheral vascular disease [74], and focal
cerebral ischemia [75]. Moreover, different investigations
have implicated VEGF in the pathology of female
reproductive tract, such as polycystic ovary syndrome,
ovarian hyperstimulation syndrome [76], endometriosis
[77], and preeclampsia [78, 79]. Besides, VEGF insuffi-
ciency might contribute to neurodegeneration, respiratory
distress and, possibly, cardiac failure [80].
2.3.3 Role of VEGF in malignancies
VEGF and its receptors are expressed in the vast majority
of human solid tumors, including those of the lung [81],
breast [82], gastrointestinal tract [83], kidney, bladder [84],
ovary, endometrium [85], brain [86], and endocrine system
[87]. In addition to tumor cells as the major source of
VEGF, stromal cells such as monocytes, macrophages, and
fibroblasts also produce VEGF [88, 89]. VEGF contributes
to tumor vascularization, progression, and invasion. To
grow beyond microscopic size, tumors need to undergo an
“angiogenic switch” to enter a vascular phase in which
blood perfusion provides a better delivery of oxygen and
nutrients and an enhanced disposal of waste products [90].
VEGF is a key mediator of this early event in tumor
angiogenesis [91]. Additionally, the endothelial cells of
intratumoral vasculature are more dependent on VEGF as a
survival factor and mitogen than those of normal vascula-
ture elsewhere [92]. VEGF-induced enhancement of endo-
thelial cell survival, proliferation, and migration together
with the resulting synthesis of other pro-angiogenic factors,
including basic fibroblast growth factor, heparin-binding
epidermal growth factor (EGF)-like growth factor, granu-
locyte colony-stimulating factor, insulin-like growth factor-
1, interleukin (IL)-6, and IL-8, provides a sustainable
angiogenesis [93, 94].
Moreover, VEGF helps tumor stroma form and mature.
By augmenting the permeability of the microvasculature,
VEGF promotes extravasation of plasma proteins and water
into the tumor milieu and the subsequent reshaping of
extracellular matrix that makes it favorable to migration and
proliferation of endothelial cells, monocytes, macrophages,
and fibroblasts. This allows final degradation of the
provisional matrix, which will be then replaced with
fibroblast-produced proteins, proteoglycans, and glycosa-
minoglycans [95]. VEGF activation of matrix-degrading
enzymes allows unhindered development of further blood
vessels [96].
VEGF is a crucial factor in tumor invasion and
metastasis as well. While tumor vascularization is a
prerequisite for tumor cells to spread by shedding into the
circulation, the newly formed, immature capillaries with
fenestrated basement membrane allow greater accessibility
for tumor cells [97]. VEGF has also been shown to enhance
tumor invasion through a direct, autocrine effect on tumor
cells [35, 98, 99]. Besides, VEGF helps the growing tumor
evade host immune responses via inhibiting functional
maturation of dendritic cells [100, 101], the most potent
antigen-presenting cells with a central role in antitumor
cell-mediated immunity. Additionally, VEGF stimulates
hematopoietic progenitor cells to initiate the pre-metastatic
niche, a regulatory event in tumor metastasis abolished by
VEGF inhibition [102].
VEGF contribution to malignancies is not exclusive to
solid tumors. VEGF is expressed in a wide variety of cell
lines derived from hematological neoplasms, including T
cell lymphoma, acute lymphoblastic leukemia, Burkitt’s
lymphoma, acute lymphocytic leukemia, histiocytic lym-
phoma, and promyelocytic leukemia [103]. Survival,
proliferation, and migration of leukemia/lymphoma cells
can be stimulated by autocrine and paracrine VEGF loops.
VEGF/VEGFR-related pathways are thought to present a
promising therapeutic target in some hematolymphoid
malignancies [104].
3 VEGF and pathogenesis of ovarian cancer
The association of VEGF and ovarian cancer has been
documented in several studies. Constitutive VEGF gene
expression in normal and neoplastic human ovaries [105] as
well as its differential expression in tumor specimens
compared to benign ovarian tissue [106, 107] has been
reported. Preclinical experiments have shown that over-
expression of VEGF can transform normal, functional
ovarian epithelium into ascites-producing, neoplastic tissue
[4, 108]. Large amounts of VEGF are secreted in ovarian
cancer in vitro and in vivo [109]. Overexpression of
intratumoral VEGF, found to correlate with poorer progno-
sis [8, 110, 111] and enhanced odds of progression [112],
has been suggested as an independent prognostic factor for
overall survival [113]. VEGF expression within omental
metastases appeared not only correlated with the extent of
omental involvement but also as an independent prognostic
indicator [114]. Elevated levels of VEGF were detected in
fluid samples from malignant cysts generated during
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ovarian cancer development which may represent a useful
biomarker of angiogenesis and tumor progression [106,
107]. VEGF levels in ovarian cancer-induced malignant
ascites are markedly elevated compared with those in
ascitic fluids of nonmalignant origin [115] being reportedly
of prognostic significance [116]. VEGF has been suggested
as a serological biomarker for clinical diagnosis and a
predictor of prognosis in patients with ovarian cancer [117–
119]. In addition, overexpression of VEGF receptors [106]
and co-receptors [120, 121] has been found in ovarian
cancer. It has been reported that VEGF gene polymor-
phisms are an independent adverse prognosticator of overall
survival [122].
VEGF expression and/or production in ovarian cancer is
induced not only by hypoxia [123–125] but also by
different growth factors, mediators, and effectors, including
insulin-like growth factor 1 [126], EGF [127], platelet-
derived growth factor (PDGF) [128], transforming growth
factor-β [129], tumor necrosis factor-α (TNF-α) [130],
TNF-like weak inducer of apoptosis [131], IL-1β [132], IL-
6 [133], endothelin-1 [134, 135], prostaglandine E2 [136],
gonadotropins [137, 138], 4-hydroxy estradiol [139], matrix
metalloproteinases (MMPs) [140], reactive oxygen species
[141], and cyclooxygenase [142, 143]. Additionally, lyso-
phosphatidic acid (LPA), a bioactive phospholipid present
in high levels in the ascitic fluid and plasma from ovarian
cancer patients, has proved to induce VEGF expression in
ovarian cancer cells [144], a process in which NF-κB
pathway has been recently implicated [145]. Moreover,
oncogenes such as PIK3CA [146] and Her-2/neu [147]
have been indicated to regulate VEGF production in
ovarian cancer cells. Here, we review different aspects of
VEGF implication in the pathogenesis of ovarian cancer.
3.1 VEGF, carcinogenesis, and tumor growth in ovarian
cancer
The theory of incessant ovulation hypothesizes that
repetitive wounding of the ovarian surface epithelium and
cell proliferation in postovulatory repair result in a stepwise
accumulation of genomic abnormalities. Ovarian epithelial
inclusion cysts occur as a result and might increase risk of
carcinogenesis by trapping cells in an environment of
aberrant autocrine or paracrine stimulation by growth
factors including VEGF which activate intracellular pro-
cesses and signaling pathways [148].
Initial studies revealed that VEGF-driven angiogenesis is
an early, crucial event in ovarian carcinogenesis [5, 106] and
implicated VEGF-regulated angiogenesis as an important
component of ovarian cancer growth [6, 149]. Schiffenbauer
et al. attributed angiogenic potential of ovarian cancer to
gonadotropin-induced expression of VEGF [137]. Later,
Zhang et al. showed that VEGF derived from ovarian cancer
cells upregulates angiopoietin 2 in host endothelial cells and
induces in a paracrine manner the remodeling of host
vasculature to support angiogenesis during tumor growth
[150]. Besides, it has been indicated that Akt1 and Akt3, two
downstream effectors of PI3K signaling pathway, have their
important roles in ovarian tumorigenesis played via regula-
tion of VEGF secretion and angiogenesis [151, 152].
Moreover, Kryczek et al. showed that tumor-derived VEGF
and CXCL12 formed a synergistic angiogenesis axis critical
for tumor neovascularization in human ovarian cancer [125].
Through locating VEGFR-2 on ovarian cancer cells
coexpressed along with VEGF, Boocock et al. raised the
possibility that an autocrine loop might directly enhance the
tumor growth [153]. This has been further validated by
other investigators. Mattern and colleagues showed the
close correlation of VEGF expression with tumor cell
proliferation [154]. Chen et al. indicated significant
correlations between the expression levels of VEGF,
VEGFR1, and VEGFR2 in ovarian cancer cells and the
activation status of signal transducer and activator of
transcription pathway (STAT3 and STAT5) in ovarian
cancer cells [155]. Distinct VEGFR-2-mediated pathways
promoting tumor growth by directly acting on ovarian
cancer cells have been demonstrated [156–158].
3.2 VEGF and ovarian cancer dissemination
Primary tumor cell with its production of a unique array of
growth factors, in particular VEGF, specifically dictates the
pattern of tumor spread [159]. Kaplan et al. showed that the
media conditioned by a tumor type, high in both PlGF and
VEGF, was able to reprogram the metastatic profile of
another tumor type, high in VEGF but low in PlGF [102].
They demonstrated that VEGF activation of VEGFR-1+
progenitor cells allows them to home to tumor-specific pre-
metastatic sites before the arrival of tumor cells. VEGF also
stimulates the migration of monocytes or macrophages that
further support the tumor stromal microenvironment [160].
In addition, tumor angiogenesis leads to the formation of
structurally abnormal blood vessels with fragmented, leaky
basement membranes which are easily penetrated by tumor
cells [161]. Moreover, Weis et al. demonstrated that Src
family kinases, playing a specific and vital role in ovarian
cancer [162], can be activated by VEGF that leads to a
breakdown in the endothelial barrier function which in turn
hastens tumor cell extravasation at metastatic sites [163].
They observed that lung colonization of ovarian tumor cells
enhanced by VEGF was alleviated by VEGF inhibitors.
VEGF contributes to ovarian cancer progression through
promoting angiogenesis as well as enhancing vascular
permeability leading to malignant effusion, as described
below. VEGF implication in ovarian cancer invasion and
metastasis has been well established by different studies.
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Through demonstrating VEGF expression in normal and
neoplastic human ovaries and identifying the malignant
ovarian epithelium as one source of ascitic VEGF, Olson et
al. implicated VEGF as an important mediator of ascites
formation and tumor metastasis in ovarian cancer [105].
They later showed that in vivo neutralization of VEGF
inhibits ovarian cancer-associated ascites formation and
tumor growth [164]. Mu and colleagues [6] indicated that
growth/metastasis of ovarian cancer cells correlates with
their VEGF-producing capacity and that angiogenesis
inhibition hampers tumor growth and metastasis through
mechanisms including the suppression of VEGF function in
vivo. Ovarian cancer cells overexpressing VEGF hold a
metastatic advantage over those lacking VEGF [163, 165].
Li et al. measured significantly higher levels of serum
VEGF in patients with metastasis as compared to
metastasis-free patients [118]. VEGF has also been impli-
cated in ovarian cancer dissemination via interacting with
tumor microenvironment. So et al. showed that LPA
induction of ovarian cancer invasion and migration is
mediated by VEGFR-2, leading to the secretion and
activation of MMP-2 and urokinase type plasminogen
activator [166]. VEGF regulation of ovarian cancer inva-
sion and migration through VEGFR-mediated secretion and
activation of MMP-2, MMP-7, and MMP-9 has been
indicated in vitro [167, 168]. Matei et al. suggested a
correlation between PDGF and VEGF networks in ovarian
cancer cells and tumors in a way that PDGF blockade and
the resultant inhibition of VEGF might affect the tumor
microenvironment which is detrimental to tumor progres-
sion [128]. Belotti and colleagues implicated a complex
cross talk between VEGF and MMPs in ovarian cancer
progression and invasion [169]. Wang and others proposed
a functionally significant role for VEGF in vasculogenic
mimicry, the formation of a fluid-conducting, matrix-rich
meshwork critical for a tumor blood supply associated with
aggressive and metastatic features [170]. They concluded
that this part is taken through VEGF upregulation of EphA2
and final activation of MMPs. VEGF might also contribute
to ovarian cancer metastasis by directly stimulating prolif-
eration, survival, and/or migration of tumor cells [171].
VEGF also allows ovarian cancer cells to evade immune
response. It has been demonstrated that VEGF directly
suppresses T cell activation [172] and that its levels in
ascitic fluid are inversely correlated with immunologically
important T cell subpopulations [116].
3.2.1 Role of VEGF in intraperitoneal dissemination
of ovarian cancer
At peritoneal metastasis, primary tumors—generally confined
to the ovaries—shed tumor cells into the peritoneum.
Malignant cells, often forming cellular aggregates or sphe-
roids, are then transported throughout the peritoneal cavity and
subsequently implant on the peritoneal wall, gastrointestinal
tract, omentum, and diaphragm. Figure 2 illustrates a proposed
model for intraperitoneal dissemination of ovarian cancer
[173, 174]. It has been suggested that intraperitoneal fluid and
peritoneal surface motion (peristalsis) are prominent mecha-
nisms controlling the patterns of spread [175]. This “seeding”
of the peritoneum and the resultant peritoneal carcinomatosis
are the most widely recognized behaviors of ovarian cancer
that is frequently associated with ascites formation [4, 171].
Peritoneal carcinomatosis is a frequent cause of death in
patients with primary advanced or recurrent ovarian cancers
[176, 177], the extent of which is a predictor of tumor
resectability and the disease prognosis [178].
Malignant ascites is a manifestation of end-stage disease
in a variety of cancers, among which ovarian cancer has
reportedly been the predominant cause [179–182]. Malig-
nant ascites arises from both tumor surface and tumor-free
peritoneum [183]. This metastatic pattern is dependent on
establishing new blood vessels at the newly seeded site [4].
VEGF contributes to intraperitoneal dissemination of
ovarian cancer by promoting neovascularization and en-
hancing vascular permeability leading to the subsequent
growth of intraperitoneal tumors, development of peritoneal
carcinomatosis, and formation of malignant ascites [184,
185]. Ovarian cancer cells [105] along with peritoneal
mesothelial cells have been identified as possible sources of
ascitic VEGF [132]. The role of VEGF in the peritoneal
metastasis of ovarian cancer has been explored by different
investigators. Senger et al. initially described VEGF as a
tumor-secreted vascular permeability factor which promotes
accumulation of ascites fluid [14, 186]. Yeo et al. later
showed that high VEGF concentrations correlate with
tumor cell growth and ascites fluid accumulation in
experimental guinea pig tumors [187]. Using animal
models of peritoneal carcinomatosis, it has been demon-
strated that overexpression of VEGF leads to an increase in
tumor and peritoneal-associated neovasculature and in-
creased peritoneal vascular permeability [188, 189]. Thus,
ascites accumulation is increased not only indirectly by
allowing tumor growth through stimulation of angiogenesis
but also directly through its ability to increase the peritoneal
vasculature permeability [190]. Byrne et al. [184] reported
that enforced expression of VEGF by ovarian cancer cells
dramatically reduced the time to onset of ascites formation
and that even tumor-free peritoneal overexpression of
VEGF was sufficient to cause ascites to accumulate.
Mesiano and colleagues [149] indicated that tumor-
derived VEGF played a pivotal role in the development of
malignant ascites from ovarian cancer. However, they raise
the possibility that intraperitoneal carcinomatosis has an
angiogenesis-dependent component represented by the
larger solid intraperitoneal tumors in need of neovasculari-
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zation for continued growth and an angiogenesis-
independent component including the thin layers of tumor
and some of the smaller solid buds surviving by passive
diffusion of nutrients from the underlying host vasculature
and the surrounding peritoneal fluid. Moreover, VEGF
inhibition hampered the formation of malignant ascites and
the progressive growth of peritoneal tumors in ovarian
cancer-bearing mice [191, 192]. Similarly, we have shown
in a murine model of ovarian cancer with peritoneal
carcinomatosis that plasma and, in particular, ascitic VEGF
levels correlate well with malignant ascites formation and
that VEGF inhibition dramatically halts ascites production
[185]. Liao et al. have recently reported that TGF-b
blockade in an experimental model of ovarian cancer
inhibited ascites production via inhibition of VEGF
production [129]. Dong and others proposed that elevated
levels of VEGF in ascites might be useful in differentiating
benign from malignant ascites [193]. In addition, an anti-
apoptotic role for VEGF in protection of the ovarian cancer
cells shed into ascetic fluid has been suggested by Sher et
al. [157]. They implicated an autocrine VEGF/VEGFR-2
loop in protecting ovarian cancer cells from apoptosis under
anchorage free growth conditions (anoikis).
Moreover, interplay between VEGF and MMPs in the
peritoneal spread of ovarian cancer has been studied in
different investigations. Yabushita et al. reported an
association between the VEGF levels and the expression
and activation of MMP-2 which they implicated in the
progression of the peritoneal involvement [194]. Belotti and
others indicated that MMPs, mainly MMP9, contributed to
the release of biologically active VEGF and consequently
to the formation of ascites [140]. Conversely, VEGF
stimulated host expression of MMP-9 in an organ-specific
manner, and VEGF inhibition reduced VEGF-induced
MMP9 expression while halting ascitic liquid formation
and intraperitoneal tumor burden [169].
3.2.2 Extraperitoneal metastasis of ovarian cancer
Upon diagnosis, metastases outside of the peritoneal cavity
are rare in ovarian cancer, and the disease is usually
confined to the peritoneal cavity at presentation. However,
extraperitoneal dissemination through lymphatics and blood
stream is increasingly recognized during treatment
[195]. The pleural cavity is the most common extraper-
itoneal site to which stage IV epithelial ovarian cancer
Fig. 2 A proposed model for intraperitoneal dissemination of ovarian
cancer [173, 174] with focus on the role of VEGF. Primary tumors are
generally confined to the ovaries. To metastasize, tumor cells undergo
epithelial–mesenchymal transition (EMT) to attain motility 1 Subse-
quently, ruptured tumor sheds malignant cells into the peritoneum 2
where they often form spheroids to survive. 3 Spheroids undergo
changes into invasive mesenchymal phenotype to maintain survival and
motility. 4 These cellular aggregates are transported throughout the
peritoneal cavity by normal peritoneal fluid and then adhere to and
implant on the peritoneum and mesothelial linings of pelvic and
abdominal organs 5, where they undergo a reverse transition (MET) 6
and disaggregation 7 to initiate metastatic growth. Through the activity
of MMPs, matrix degradation occurs 8 and invasive tumor cells
infiltrate the mesothelial lining and the extracellular matrix 9. Cytokines
and growth factors, such as VEGF, TNF-α, IL-6, IL-8, and bFGF,
contribute to EMT and invasiveness of spheroids via autocrine and
paracrine loops. VEGF is also significantly involved in different steps of
the process, including primary tumor angiogenesis, neovascularization
at newly seeded sites, MMP-mediated matrix degradation, and
malignant ascites formation
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preferentially metastasizes [196]. The liver and lung are
other common sites of metastasis. VEGF contribution to
ovarian metastasis of the lymph nodes, lung, and liver has
been reported [6, 163]. VEGF-C, another member of the
VEGF family, has been implicated in lymphatic spread of
ovarian cancer [197].
4 VEGF/VEGFR-targeted therapy in ovarian cancer
Based on the major role played by VEGF in the
pathogenesis of ovarian cancer along with the promising
preclinical results, agents targeting VEGF signaling path-
ways have been under clinical investigation for activity in
ovarian cancer (Table 1).
4.1 VEGF neutralization
Known as the first anti-VEGF agent approved by Food and
Drug Administration in 2004 for clinical use in colorectal
cancer, bevacizumab has been the first and most studied
anti-VEGF agent in clinical evaluation for ovarian cancer.
Bevacizumab is a recombinant humanized VEGF mono-
clonal antibody derived from its murine equivalent A4.6.1
that targets all active isoforms of VEGF, preventing them
from binding to VEGFRs [198]. In initial reports, Mesiano
et al. demonstrated that A4.6.1 inhibited subcutaneous and
intraperitoneal tumor growth and completely prevented
ascites production in an athymic mouse model of ovarian
cancer [149]. The same group later reported additive or
synergistic effects of this antibody in combination therapy
as enhanced sensitivity to paclitaxel and marked reduction
of tumor growth and ascites formation [199]. Using a
murine ovarian cancer model, Mabuchi et al. reported
significant antitumor activity of bevacizumab as a single
agent or in combination with cisplatin and concluded that it
might also prolong survival when used as maintenance
therapy after a complete response to cisplatin-based
chemotherapy [200]. Preclinical studies employing VEGF
immunoneutralization laid the basis for clinical evaluation
of bevacizumab in ovarian cancer. Table 2 summarizes the
accessible results from some of these investigations.
Aflibercept (VEGF trap) [201] is a soluble decoy
receptor that binds and inactivates some members of the
VEGF family, including VEGF, VEGF-B, and PlGF. Byrne
et al. found that systemic administration of aflibercept
prevented ascites accumulation, inhibited the growth of
disseminated cancer, and resulted in dramatic remodeling of
the blood vessels in an experimental model of ovarian
cancer [184]. Hu et al. later showed that aflibercept plus
paclitaxel strikingly reduced tumor burden and inhibited
ascites while prolonging survival [202]. Aflibercept has
further been investigated in some clinical studies (Table 3).
4.2 Receptor tyrosine kinase inhibitors
4.2.1 VEGFR antagonists
Agents targeting VEGF receptors have been evaluated for
the use in the treatment of ovarian cancer. Ramucirumab, a
fully humanized monoclonal antibody specifically blocking
VEGFR-2, resulted in reduced tumor growth, increased
Table 1 Therapeutic agents targeting VEGF/VEGFR in clinical development for ovarian cancer
Type Drug Target(s)
VEGF binders Bevacizumab VEGF (all isoforms)
Aflibercept VEGF, VEGF-B, PlGF
Receptor tyrosine kinase inhibitors VEGFR inhibitors Ramucirumab VEGFR2
Cediranib VEGFR1-3, c-Kit, PDGFR-β
Semaxanib VEGFR2
Multiple RTK inhibitors Sunitinib VEGFR1-3, Flt-3, PDGFR-α, PDGFR-β,
c-Kit, CSF-1R, RET
Sorafenib VEGFR1-3, PDGFR-β, Flt-3, c-Kit, Raf-1
Vatalanib VEGFR1-3, PDGFR-β, c-Kit, c-Fms
Intedanib VEGFR1-3, PDGFR-α, PDGFR-β, FGFR1-3
Pazopanib VEGFR1-2, PDGFR-β, c-Kit
Motesanib VEGFR1-3, PDGFR, c-Kit
Vandetanib VEGFR2-3, EGFR
AEE788 VEGFR, EGFR
CSF-1 R colony-stimulating factor 1 receptor, EGFR epidermal growth factor receptor, FGFR fibroblast growth factor receptor, PDGFR platelet-
derived growth factor receptor, PlGF placenta growth factor, RTK receptor tyrosine kinase, VEGF vascular endothelial growth factor, VEGFR
vascular endothelial growth factor receptor
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apoptosis, and decreased tumor microvessel proliferation
and density in vivo [203]. Following a phase I evaluation
[204], it is currently being assessed in a phase II trial
(NCT00721162) as monotherapy in patients with persistent
or recurrent epithelial ovarian cancer. Cediranib, a tyrosine
kinase inhibitor selectively blocking VEGFR1-3, platelet-
derived growth factor receptor-β (PDGFR-β), and c-Kit,
has been shown to inhibit the growth of human tumor
xenografts, including ovarian cancer, in a dose-dependent
manner [205]. Single-agent activity of cediranib in phase II
trials has been reported [206, 207]. A number of the clinical
studies testing cediranib in ovarian cancer are ongoing,
including a three-arm randomized placebo-controlled phase
III trial set to investigate cediranib in combination with
platinum-based chemotherapy and as a single agent
maintenance therapy in patients with platinum-sensitive
relapsed ovarian cancer (ICON6). In a study by Holtz et al.
[208], semaxanib reduced tumor growth and microvessel
density in ovarian cancer tumors with high VEGF expres-
sion. A phase I study of semaxanib in combination with
carboplatin in patients with platinum-refractory ovarian
cancer (NCT00006155) has been completed (results
awaited).
4.2.2 Agents targeting multiple receptor tyrosine kinases
As a single agent, sunitinib has demonstrated efficacy in
advanced ovarian cancer in both preclinical [209] and clinical
[210, 211] studies. Sorafenib, in a study by Matsumura et al.,
was shown to have an antitumor effect against ovarian clear
cell carcinoma [212]. It has shown some efficacy in phase I/
II trials [213–215] and is now under further clinical
investigations. In an ovarian cancer mouse model, single-
agent vatalanib reduced ascites and tumor growth and
yielded increased survival [191]. In a phase I study of
vatalanib combined with carboplatin and paclitaxel in
advanced ovarian cancer, Shroder et al. showed that
vatalanib was feasible and well tolerated [216]. Monotherapy
with vandetanib showed a significant antitumor effect in an
ovarian cancer nude mice model [217]. However, no
significant clinical benefit was made by vandetanib mono-
therapy in patients with recurrent ovarian cancer in a phase II
clinical trial [218]. Its efficacy in combination with docetaxel
in persistent or recurrent ovarian cancer will be assessed in a
phase II clinical trial (NCT00872989). In a study by Hilberg
et al. [219], intedanib demonstrated high activity at a well-
tolerated dose as decreased vessel density and vessel
integrity, and profound growth inhibition in all tested tumor
models. In a phase II trial, maintenance intedanib delayed
disease progression in previously treated ovarian cancer
patients [220]. To investigate its efficacy and safety,
intedanib combined with carboplatin and paclitaxel is
currently being examined in a randomized, double-blind
phase III trial in patients with advanced ovarian cancer
(NCT01015118). In an animal model of ovarian cancer,
treatment with AEE788 plus paclitaxel significantly reduced
tumor weight and increased survival of nude mice implanted
with paclitaxel-sensitive cell lines compared with those
treated with AEE788 alone or paclitaxel alone [221]. Also,
metronomic docetaxel chemotherapy plus AEE788 was
effective even in the taxane-resistant model [222]. A phase
I/II randomized study of AEE788 in adult patients with
advanced cancer (histologically confirmed solid tumors) has
been completed (NCT00118456) and results are awaited.
Pazopanib, alone or in combination with metronomic top-
otecan, showed anti-angiogenic and antitumor activity in a
preclinical model of ovarian cancer [223]. Friedlander et al.
reported pazopanib activity in a phase II trial in women with
advanced epithelial ovarian cancer [224]. Other trials
evaluating pazopanib efficacy as mono- or combination
therapy are underway. Motesanib, that indicated antitumor
activity in animal models [225], is now under clinical
investigation in a phase II clinical trial (NCT00574951).
4.3 VEGF-targeted therapy: current challenges
Adverse effects such as hypertension, proteinuria, bowel
perforation, impaired wound healing, hemorrhage, and
arterial thrombotic events represent the most common
toxicities associated with VEGF-targeted therapy [226,
227]. Inherent [228] and/or acquired resistance/refractori-
ness [226, 229] might complicate the treatment as well.
Divergent effect of receptor tyrosine kinase blockade,
including VEGFR inhibition, on primary tumor growth
Table 3 Released data of three phase II clinical trials evaluating aflibercept (VEGF trap) in ovarian cancer
Investigators Phase Target Results
Tew et al. [256] II Platinum-resistant and topotecan and/or liposomal
doxorubicin-resistant advanced ovarian cancer
Preliminary results showed a partial response of 11%.
Colombo et al. [257] II Platinum-resistant and topotecan and/or liposomal
doxorubicin-resistant advanced ovarian cancer with
recurrent symptomatic malignant ascites
First results demonstrated the efficacy of two weekly
intravenous aflibercept in prolonging the time to
repeat paracentesis in 8 out of 10 evaluable patients.
Coleman et al. [258] II Recurrent EOC, PPC, FTC ORR, 54%; CR, 21.7; MPFS, 6.2; MOS, 24.3
EOC epithelial ovarian cancer, PPC primary peritoneal cancer, FTC fallopian tube cancer, VEGF vascular endothelial growth factor
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and metastasis leading to enhanced invasion and accelerated
metastasis has been reported in preclinical studies [230, 231].
However, the clinical relevance of these findings is unclear
and limited to small studies or case reports [232].
As improving overall survival while maintaining the
quality of life remains the goal of all cancer treatment
[233], efficacy of extended adjuvant bevacizumab in
unselected populations may not be justified by the clinical
benefits reported thus far [234]. Consistently, a recent
analysis of GOG218 study has raised doubts about cost-
effectiveness of utilizing bevacizumab in the adjuvant
management and maintenance therapy of patients with
advanced ovarian cancer [235, 236]. This might be in part
attributed to limitations of predictive preclinical models and
thus lack of appropriate preclinical testing that precedes
clinical settings [232]. Besides, accurate predictors of
prognosis and ideal surrogate biomarkers required for
individualization of VEGF-targeted therapy are to be
identified and clinically validated [227].
5 Conclusion
The role of VEGF in ovarian cancer growth and progres-
sion is well established. Through induction of tumor
angiogenesis and vascular permeability, VEGF has a major
contribution to the pathophysiology of ovarian cancer.
VEGF promotes tumor growth and facilitates malignant
cell invasion and dissemination. Peritoneal carcinomatosis
with malignant ascites formation is the prominent pattern of
ovarian cancer spread in which VEGF is significantly
involved, further highlighting the crucial part played by
VEGF in the progressive course of the disease. Preclinical
data obtained over the last 15 years or so clearly
demonstrate a central role of VEGF inhibitors in the
management of ovarian cancer. On the other hand, the
complexity of VEGF signaling cascade and the interacting
pathways as well as the failure of preclinical studies in
closely mimicking actual clinical settings represent major
restrictions and barriers in translating preclinical promises
to the clinic. However, this has not hindered the extensive
evaluation of bevacizumab and other VEGF-targeted agents
in phase II and III clinical trials, and VEGF still remains a
target in the treatment of ovarian cancer.
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